Adverse events of antifibrinolytic agents · People with a haematological disorder
1 finding from 1 review
Number of participants with any bleeding · People with a haematological disorder
1 finding from 1 review
Thromboembolism · People with a haematological disorder
1 finding from 1 review
Mortality (all‐cause) ‐ not reported · People with a haematological disorder
1 finding from 1 review
Number of platelet transfusions per participant up to 30 days from study entry · People with a haematological disorder
1 finding from 1 review
Adverse events associated with transfusion · People with a haematological disorder
1 finding from 1 review
Quality of life ‐ not reported · People with a haematological disorder
1 finding from 1 review
Minor bleeding ‐ not reported · ambulatory patients with multiple myeloma receiving immunomodulatory agents
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Minor bleeding · ambulatory patients with multiple myeloma receiving immunomodulatory agents
It is very uncertain whether aspirin (ASA) changes minor bleeding compared with low molecular weight heparin (LMWH) (very low certainty).
1 finding from 1 review
Minor bleeding ‐ not reported · ambulatory patients with multiple myeloma receiving immunomodulatory agents
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Minor bleeding · ambulatory patients with multiple myeloma receiving immunomodulatory agents
It is very uncertain whether vitamin K antagonist (VKA) changes minor bleeding compared with low molecular weight heparin (LMWH) (very low certainty).
1 finding from 1 review
Minor bleeding ‐ not reported · ambulatory patients with multiple myeloma receiving immunomodulatory agents
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Minor bleeding · ambulatory patients with multiple myeloma receiving immunomodulatory agents
It is very uncertain whether aspirin (ASA) changes minor bleeding compared with direct oral anticoagulants (DOAC) (very low certainty).
1 finding from 1 review
RR 5 [0.31, 79.94]
1 study · 8 participants
Very low
Minor bleeding · ambulatory patients with multiple myeloma receiving immunomodulatory agents
It is very uncertain whether aspirin (ASA) changes minor bleeding compared with vitamin K antagonist (VKA) (very low certainty).
1 finding from 1 review
Number of participants with minor procedure‐related bleeding within 7 days of surgery · people with a low platelet count
It is very uncertain whether prophylactic platelet transfusion prior to surgery changes number of participants with minor procedure‐related bleeding within… compared with alternative treatments (very low certainty).
1 finding from 1 review
Intervention not reported
Number of participants with minor procedure‐related bleeding within 7 days of surgery · people with a low platelet count
1 finding from 1 review
Number of participants with minor procedure‐related bleeding within 7 days of surgery · people with a low platelet count
It is very uncertain whether prophylactic platelet transfusion prior to surgery changes the number of participants with minor procedure‐related bleeding… compared with no prophylactic platelet transfusion prior to surgery (very low certainty).
1 finding from 1 review
Number of participants with minor procedure‐related bleeding within 7 days of surgery · people with abnormal coagulation requiring a central venous catheter
It is very uncertain whether comparison of plasma transfusions changes minor procedure‐related bleeding compared with no plasma transfusions when the INR is 1.5 prior to central venous… (very low certainty).
1 finding from 1 review
Intervention not reported
Minor bleeding [ · patients with polycythaemia vera
The intervention probably leads to higher minor bleeding [ (moderate certainty).
1 finding from 1 review
Mortality (calculated instead of overall survival) · adults with acute myeloid leukaemia (AML) (non‐acute promyelocytic leukaemia (APL))
ATRA in addition to chemotherapy showed no clear difference in mortality (instead of overall survival) compared with chemotherapy only (moderate certainty).
1 finding from 1 review